We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

168 hedge funds and large institutions have $302M invested in Meridian Bioscience Inc in 2020 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 53 increasing their positions, 57 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more call options, than puts

Call options by funds: $502K | Put options by funds: $458K

3% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 31

7% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 57

1% less funds holding

Funds holding: 170168 (-2)

17% less capital invested

Capital invested by funds: $363M → $302M (-$60.7M)

Holders
168
Holders Change
-2
Holders Change %
-1.18%
% of All Funds
3.7%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
30
Increased
53
Reduced
57
Closed
31
Calls
$502K
Puts
$458K
Net Calls
+$44K
Net Calls Change
+$75K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$55.2M -$2.83M -335,720 -5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$36.1M -$2.54M -302,055 -7%
Renaissance Technologies
3
Renaissance Technologies
New York
$26.5M -$1.13M -134,548 -4%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$17M +$98.2K +11,667 +0.6%
State Street
5
State Street
Massachusetts
$15.4M +$2M +237,787 +15%
SFM
6
Systematic Financial Management
New Jersey
$10.4M -$717K -85,199 -6%
Millennium Management
7
Millennium Management
New York
$9.81M +$8.46M +1,005,374 +617%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$7.42M +$181K +21,482 +2%
N
9
Nuveen
North Carolina
$6.42M +$2.06M +244,478 +47%
JP Morgan Chase
10
JP Morgan Chase
New York
$5.71M +$3.54M +420,681 +163%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$5.64M +$487K +57,882 +9%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$5.38M +$89.1K +10,588 +2%
Assenagon Asset Management
13
Assenagon Asset Management
Luxembourg
$5.1M +$783K +92,964 +18%
Northern Trust
14
Northern Trust
Illinois
$4.63M -$62.9K -7,476 -1%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$4.51M -$146K -17,307 -3%
Wells Fargo
16
Wells Fargo
California
$4.23M -$2.36M -280,589 -36%
KCM
17
Kennedy Capital Management
Missouri
$3.51M +$3.51M +417,352 New
Invesco
18
Invesco
Georgia
$3.08M +$158K +18,741 +5%
Principal Financial Group
19
Principal Financial Group
Iowa
$2.91M -$108K -12,887 -4%
Victory Capital Management
20
Victory Capital Management
Texas
$2.69M +$1.27M +151,014 +89%
Deutsche Bank
21
Deutsche Bank
Germany
$2.57M -$362K -42,970 -12%
AQR Capital Management
22
AQR Capital Management
Connecticut
$2.38M +$44.5K +5,291 +2%
Norges Bank
23
Norges Bank
Norway
$2.36M
Charles Schwab
24
Charles Schwab
California
$2.27M +$37.3K +4,430 +2%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$2.21M +$301K +35,697 +16%

VIVO Hedge Fund Activity: Q1 2020 in Review

168 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2020, worth a combined $302M — down 17% from $363M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of VIVO and 30 opened new positions — a net loss of 1 holder — while 57 trimmed existing stakes and 53 added.

The largest buyer was Millennium Management, adding an estimated $8.46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $5.01M sold.

  • 168 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2020, down from 170 in Q4 2019.
  • Funds reported $302M of Meridian Bioscience Inc stock for Q1 2020, down 17% quarter-over-quarter.
  • 30 funds opened new Meridian Bioscience Inc positions in Q1 2020 and 31 closed out, a net change of -1 holder.
  • The largest Meridian Bioscience Inc buyer in Q1 2020 was Millennium Management, an estimated $8.46M added.
  • The largest Meridian Bioscience Inc seller in Q1 2020 was Point72 Asset Management, an estimated $5.01M sold.

Based on aggregated 13F filings for Q1 2020.